Use of a biomarker in exposure-response analysis to support dose selection for fingolimod.
about
Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.
P2860
Use of a biomarker in exposure-response analysis to support dose selection for fingolimod.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Use of a biomarker in exposure ...... dose selection for fingolimod.
@en
Use of a biomarker in exposure ...... dose selection for fingolimod.
@nl
type
label
Use of a biomarker in exposure ...... dose selection for fingolimod.
@en
Use of a biomarker in exposure ...... dose selection for fingolimod.
@nl
prefLabel
Use of a biomarker in exposure ...... dose selection for fingolimod.
@en
Use of a biomarker in exposure ...... dose selection for fingolimod.
@nl
P2860
P356
P1476
Use of a biomarker in exposure ...... dose selection for fingolimod.
@en
P2860
P356
10.1038/PSP.2013.44
P577
2013-08-21T00:00:00Z